SOURCE: Bellwether Report

May 12, 2005 12:26 ET

BWR Assesses These Four Nasdaq Top Gainers: MUSE, INNO, FWHT, and BMRN

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report.

TORONTO -- (MARKET WIRE) -- May 12, 2005 -- The Bellwether Report is the leading online financial newsletter, focusing on small-cap emerging growth opportunities. We strive to introduce investors to truly undervalued opportunities in a time friendly fashion, allowing for optimal entry points and profitable exit points.

Today, BWR will be closely assessing these promising companies on the Nasdaq Exchange: Micromuse Inc. (NASDAQ: MUSE), Innovo Group Inc. (NASDAQ: INNO), FindWhat.com Inc. (NASDAQ: FWHT) and finally BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). For more information on the BWR or any of the above mentioned companies feel free to visit www.bellwetherreport.com for a free no obligation 30 day trial of our service. Remember...No credit card required.

Micromuse Inc. develops, markets, and supports a family of scalable, highly configurable, rapidly deployable software solutions for businesses. This morning the shares of this company jumped 10% following today's upgrade by Raymond James. In the first 6 months ended 3/31/05, revenues rose 2% to $76.8 million.

Innovo Group Inc. is engaged in the design, development, and worldwide marketing of branded and private-label denim and denim-related products. We will continue to follow the progress of this company for future developments. For the three months ended 2/26/05, revenues increased 78% to $23.1 million.

FindWhat.com Inc. offers marketing and services to help businesses throughout the business cycle in reaching prospects, converting prospects to customers and then retaining those customers. Stock rose 7% this morning after a mistrial was declared in a patent infringement dispute with Overture Services, a unit of Yahoo. Revenues rose from $72.2 million to $169.5 million for fiscal year ended 12/31/04.

Finally, BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Shares were up this morning 7% following today's upgrade by Rodman and Renshaw. Revenues increased with this company by 54% to $18.6 million for fiscal year ended 12/31/04.

For 30 days complimentary with the BWR service feel free to visit www.bellwetherreport.com and sign up. No credit card needed!!

The Bellwether Report to date has not been compensated by any of the above-mentioned companies.

Contact Information